Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Autor: Xu, Linlin *, Shadman, Mazyar, Ponakala, Anusha *, Flinn, Ian W., Levy, Moshe Yair, Porter, Ryan *, Burke, John M., Zafar, Syed F., Cultrera, Jennifer L. *, Misleh, Jamal *, Kingsley, Edwin C., Yimer, Habte, Freeman, Benjamin *, Chaudhry, Arvind *, Tumula, Praveen K. *, Gandhi, Mitul, Cohen, Aileen *, Chen, Dih-Yih *, Manda, Sudhir, Sharman, Jeff P., Ramakrishnan, Vanitha *
Zdroj: In Blood 15 November 2022 140 Supplement 1:9269-9271
Databáze: ScienceDirect